Vertex Pharmaceutical (VRTX +0.7%) says data from its follow-up study of Kalydeco was positive....

|About: Vertex Pharmaceuticals Inco... (VRTX)|By:, SA News Editor

Vertex Pharmaceutical (VRTX +0.7%) says data from its follow-up study of Kalydeco was positive. Tests showed improvements in lung function, respiratory symptoms and weight gain among people who were treated with the drug for 48 weeks in one of two pivotal studies, and were durable for up to 96 total weeks of treatment.